DKSH N/ CH0126673539 /
2024-03-28 5:30:28 PM | Chg. -2.60 | Volume | Bid5:40:00 PM | Ask5:40:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
61.35CHF | -4.07% | 125,562 Turnover: 7.72 mill. |
61.10Bid Size: 200 | 63.95Ask Size: 17,775 | 3.99 bill.CHF | 3.67% | 21.91 |
GlobeNewswire
03-20
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
GlobeNewswire
03-05
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
GlobeNewswire
02-26
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purc...
GlobeNewswire
02-24
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interc...
GlobeNewswire
02-15
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
GlobeNewswire
01-29
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Bios...
GlobeNewswire
01-19
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
GlobeNewswire
01-10
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
GlobeNewswire
01-03
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT...
GlobeNewswire
2023-11-29
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Bios...
GlobeNewswire
2023-11-28
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
GlobeNewswire
2023-11-21
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Hos...
GlobeNewswire
2023-11-14
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First...
GlobeNewswire
2023-11-10
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelar...
GlobeNewswire
2023-10-12
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
GlobeNewswire
2023-10-03
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Comme...
GlobeNewswire
2023-09-25
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
GlobeNewswire
2023-09-20
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar C...
GlobeNewswire
2023-08-30
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update